Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: Implication for extended endocrine therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages

  Yu, Ke Da ^a   Wu, Jiong ^a   Shen, Zhen Zhou ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SPECIFIC MORTALITY; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PATIENT SELECTION; PROGNOSIS; RECEPTORS, ESTROGEN; SEER PROGRAM; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84870746438     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2423     Document Type: Article

References (34)

1. Jatoi I, Anderson WF, Jeong JH, Redmond CK 2011 Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 29:2301-2304
2. Burdette-Radoux S, Muss HB 2009 A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy? Clin Breast Cancer 9 Suppl 1:S37-S41
3. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ 2010 American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
4. Fisher B, Dignam J, Bryant J, Wolmark N 2001 Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690 (Pubitemid 32492809)
5. Tormey DC, Gray R, Falkson HC 1996 Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph nodepositive breast cancer. Eastern Cooperative Oncology Group. J Natl Cancer Inst 88:1828-1833 (Pubitemid 26425057)
6. Stewart HJ, Prescott RJ, Forrest AP 2001 Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 93:456-462 (Pubitemid 32266538)
7. Peto R, Davies C 2008 ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women-preliminary results. Breast Cancer Res Treat 109:586-586
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802 (Pubitemid 37362955)
9. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE 2012 Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCICCTGMA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 30:718-721
10. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271 (Pubitemid 41535367)
11. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer Jr CE, Costantino JP, Wolmark N 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 26:1965-1971
12. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845-1853 (Pubitemid 351767193)
13. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
14. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN 2003 Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118 (Pubitemid 36223023)
15. Hankey BF, Ries LA, Edwards BK 1999 The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev 8:1117-1121 (Pubitemid 30004912)
16. Lambert PC, Royston P 2009 Further development of flexible parametric models for survival analysis. Stata J 9:265-290
17. Royston P, Parmar MK 2002 Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21:2175-2197 (Pubitemid 34830755)
18. Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K 2011 Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 29:4014-4021
19. Yu KD, Li S, Shao ZM 2011 Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery. Oncologist 16:1101-1110
20. Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP 2009 Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. Am J Epidemiol 169:1463-1470
21. Wo JY, Chen K, Neville BA, Lin NU, Punglia RS 2011 Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29:2619-2627
22. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM 1998 Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52:227-237 (Pubitemid 29056098)
23. Anderson WF, Chen BE, Jatoi I, Rosenberg PS 2006 Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 100:121-126
24. Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N 2009 Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 116:595-602
25. Jatoi I, Chen BE, Anderson WF, Rosenberg PS 2007 Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683-1690 (Pubitemid 46797948)
26. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ 2006 Validation and clinical utility of a 70-gene prognostic signature forwomenwith node-negative breast cancer. J Natl Cancer Inst 98:1183-1192 (Pubitemid 44390989)
27. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE 2008 Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol 26:1956-1964
28. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, François E, Namer M, Ferrero JM, Milano G 1996 Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59:401-410 (Pubitemid 26151622)
29. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N 2005 Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652-1662 (Pubitemid 41672231)
30. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N 2008 Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 122:1089-1094 (Pubitemid 351214007)
31. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N 2004 Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 96:516-523 (Pubitemid 38559575)
32. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK 2005 Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 23:4687-4694 (Pubitemid 46224071)
33. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N 2011 Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478-488
34. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD 2011 Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21-29